Vivos Therapeutics (NasdaqCM:VVOS) Fireside Chat December 16, 2025 11:00 AM ET Company ParticipantsR. Kirk Huntsman - CEOBrad Amman - CFOModeratorLet me start. As the year draws to a close, 2025 stands out as one of the most pivotal in the company's history. It marked the launch of a potentially transformative shift in Vivos' business model, highlighted by the June acquisition of the Sleep Center of Nevada, or SCN. Before we get into the operational progress of the transition, Kirk, could you start by shari ...

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Company ParticipantsBrad Amman - CFOKirk Huntsman - Chairman and CEOConference Call ParticipantsRobert Sassoon - Senior Research AnalystLucas Ward - Senior Research AnalystOperatorGood day, everyone, and welcome to the Vivos Third Quarter 2025 conference call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, an ...

睡眠障碍现状与影响 - 中国18岁及以上人群中48.5%存在睡眠困扰，女性51.1%高于男性45.9%，且随年龄增长困扰率上升[2] - 睡眠障碍与精神疾病（如抑郁、疼痛）存在双向影响关系，可能加剧疾病发展[2] - 阿尔茨海默病（AD）患者或轻度认知障碍（MCI）患者睡眠障碍发生率超过70%，MCI阶段已出现代谢与睡眠异常[3] - 中国60岁以上AD发病率4%-6%（约1699万患者），MCI患病率15.5%（3877余万患者），澳门地区发病率更高[3] 脑机接口技术应用 - 非侵入式脑机接口推动健康管理从"被动治疗"转向"主动预防"，广东省智能科学与技术研究院强调其作为底层技术的重要性[1][2] - 澳门大学团队探索可穿戴多模态睡眠脑电+近红外脑氧代谢成像技术，用于MCI早期筛查和AD干预[2][3] - 燧人医疗发布首款消费级多模态梦境脑机接口设备"梦邻"，具备脑电监测、睡眠调控、AI分析四大功能，8月底量产[6][7] 睡眠医学发展瓶颈 - 国内睡眠诊断/治疗认知水平较低，医生对睡眠机制掌握不足导致治疗不到位[4] - 睡眠神经调控领域存在基础研究向临床转化瓶颈，需突破普惠型技术障碍[1] - 医疗级产品开发面临产程长、资金需求大等挑战，需产业链协同推进[7] 睡眠健康市场前景 - 中国睡眠经济市场规模从2016年2616.3亿元增至2023年4955.8亿元，预计2027年达6586.8亿元[6] - 失眠与打鼾人群构成民用睡眠产品两大主力需求，行业潜在规模达万亿级[6] - 消费级产品可加速市场教育，为产业化奠定基础，吸引资本关注[7]